Bayer
This article was originally published in The Tan Sheet
Executive Summary
Consumer Care Division sales drop of 26.6% to $385.8 mil. is "attributable to currency and portfolio trends," CEO Werner Wenning says in Aug. 5 earnings call. "Without these factors, sales were up 4.9%. Business in the U.S. was especially strong due to the nutritionals and Alka-Seltzer line. Sales were up in Mexico, Brazil and Argentina," the exec notes. August launch of Alka-Seltzer Plus Ready Release quick dissolve tablets could enhance brand's strong performance further in third quarter (1"The Tan Sheet" June 23, 2003, p. 10)...
You may also be interested in...
NACDS In Brief
Bayer: Alka-Seltzer Plus Ready Release quick dissolve tablets slated to ship in early August, firm says at National Association of Chain Drug Stores Marketplace in San Diego June 8-10. New delivery form "melts in your mouth" with "no water needed," labeling notes. Tablets in blister-pack 12-count boxes contain acetaminophen and pseudoephedrine, will be indicated for nasal congestion, runny nose, sneezing and sinus pressure. Consumers are advised to take two tablets for symptom relief; flavors include cool mint and orange zest. Bayer will support the line extension with television and print ads, as well as FSI drops in October, November and December...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.